Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- GBX +2.9%, NG +0.7%
M&A news:
- LLEX +16.7% (to acquire over 4,000 net contiguous/overlapping acres from a private seller for approximately $45.6MM in cash)
- BSFT +7% (higher on PE speculation)
- TWTR +1.7% (Disney (DIS) CEO confirms the company weighed a bid for Twitter, but ultimately moved in another direction by agreeing to acquire majority ownership of BAMTech)
Other news:
- CATB +52.7% (reports positive results from Phase 2 MoveDMD trial; plans to initiate Phase 3 in 1H18)
- CTMX +37.4% (CytomX Therapeutics and Amgen announce strategic collaboration in immuno-oncology; Amgen to make upfront payment of $40 mln and purchase $20 mln of common stock)
- CAPR +25% (reports 'that teens and young men in the advanced stages of Duchenne muscular dystrophy experienced meaningful improvements in cardiac and upper limb function after a single dose of Capricor's lead investigational product, CAP-1002')
- VKTX +20.7% (announces 'positive' top-line results from a 25-week proof-of-concept study of VK0214)
- FOLD +16.2% (announces additional 'positive' results from a Phase 1/2 clinical study to investigate ATB200/AT2221)
- MTBC +15.5% (continued strength)
- MYL +13.9% (receives FDA approval for generic Copaxone)
- CLSN +11.6% (continued strength)
- MTFB +8.3% (reports Topline Results for iclaprim met the primary endpoint )
- GBT +4% (Point72 Asset Management increases passive stake )
- I +1.9% (after seeing late move higher after analyst said jointly filed a submission with the FCC proposing the sharing of C-band spectrum for use in 5G)
- MGI +1.3% (following afternoon weakness on reports that Alibaba's (BABA) Ant Financial deal to acquire MGI might get criticism from Senator Schumer)
Analyst comments:
- CPST +7.3% (upgraded to Outperform from Perform at Oppenheimer)
- FCEL +5.8% (initiated with a Outperform at Oppenheimer)
- VNET +5% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- NFLX +1.3% (target raised to $225 from $190 at UBS)
- SMPL +1.1% (initiated with a Buy at Goldman)
- TSLA +1% (initiated with a Buy at Instinet)
- TTWO +0.9% (initiated with an Overweight at Barclays)